Biomarkers for Alzheimer's disease.
Alzheimer's disease (AD) is a horribly debilitating disease that will increase in prevalence as the populations of the USA and Europe continue to age. It is expected that the USA alone will see some 16 million cases by 2050. At present, there is no cure for the disease and early diagnosis is all but impossible. The onset of disease is not manifested clinically and little is known regarding the cause of nonfamiliar AD. There is a need for biomarkers associated with AD to aid the diagnosis of this disease and to detect progression. Especially needed are biomarkers to monitor the effect of new drugs and therapeutic strategies as they are developed. A biomarker may be a genetic trait, a biochemical change, such as a protein, peptide or metabolite, or a change in a structural or functional feature detected using imaging technology. This review aims to cover the important field of biomarker research in association with AD.
Ward
Malcolm
M
Proteome Sciences plc, South Wing Laboratory (PO 045), Institute of Psychiatry, London, SE5 8AF, UK. malcolm.ward@proteomics.com
D000544:Alzheimer Disease / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics / Q000473:pathology; D015415:Biomarkers / Q000032:analysis*; D001798:Blood Proteins / Q000032:analysis; D001921:Brain / Q000473:pathology; D002556:Cerebrospinal Fluid Proteins / Q000032:analysis; D005060:Europe / Q000453:epidemiology; D020022:Genetic Predisposition to Disease; D006801:Humans; D058225:Plaque, Amyloid / Q000473:pathology; D015995:Prevalence; D014481:United States / Q000453:epidemiology
D015415:Biomarkers; D001798:Blood Proteins; D002556:Cerebrospinal Fluid Proteins